NASDAQ:OPRX OptimizeRx (OPRX) Stock Price, News & Analysis $5.62 -0.16 (-2.75%) As of 01:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About OptimizeRx Stock (NASDAQ:OPRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get OptimizeRx alerts:Sign Up Key Stats Today's Range$5.47▼$5.9250-Day Range$4.75▼$6.6452-Week Range$3.78▼$16.65Volume90,270 shsAverage Volume146,860 shsMarket Capitalization$103.54 millionP/E RatioN/ADividend YieldN/APrice Target$9.06Consensus RatingModerate Buy Company OverviewOptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.Read More… OptimizeRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreOPRX MarketRank™: OptimizeRx scored higher than 66% of companies evaluated by MarketBeat, and ranked 296th out of 657 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingOptimizeRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageOptimizeRx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about OptimizeRx's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for OptimizeRx are expected to grow in the coming year, from ($0.33) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptimizeRx is -4.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptimizeRx is -4.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOptimizeRx has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about OptimizeRx's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.14% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in OptimizeRx has recently increased by 4.92%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOptimizeRx does not currently pay a dividend.Dividend GrowthOptimizeRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.14% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in OptimizeRx has recently increased by 4.92%, indicating that investor sentiment is decreasing. News and Social Media1.1 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for OptimizeRx this week, compared to 2 articles on an average week.Search Interest6 people have searched for OPRX on MarketBeat in the last 30 days. MarketBeat Follows2 people have added OptimizeRx to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, OptimizeRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $100,200.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.10% of the stock of OptimizeRx is held by insiders.Percentage Held by Institutions76.47% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OptimizeRx's insider trading history. Receive OPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter. Email Address OPRX Stock News HeadlinesOne OptimizeRx Insider Raised Their Stake In The Previous YearFebruary 12, 2025 | uk.finance.yahoo.comOptimizeRX edges higher as holder pushes firm to explore a saleFebruary 6, 2025 | msn.comHere’s how you could profit from Elon’s NVIDIA partnership"Elon's #1 AI Stock" SET TO SOAR Forget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful. After all, ChatGPT just works online... While Elon's AI works in the real world.February 24, 2025 | Behind the Markets (Ad)Strong week for OptimizeRx (NASDAQ:OPRX) shareholders doesn't alleviate pain of three-year lossJanuary 24, 2025 | finance.yahoo.comOptimizeRx (OPRX) was downgraded to a Hold Rating at Stifel NicolausJanuary 13, 2025 | markets.businessinsider.comOptimizeRx downgraded to Sector Perform from Outperform at RBC CapitalJanuary 8, 2025 | markets.businessinsider.comOptimizeRx (OPRX) was downgraded to a Hold Rating at RBC CapitalJanuary 8, 2025 | markets.businessinsider.comOptimizeRx downgraded to "sector perform" by RBC amid slower growth outlookJanuary 8, 2025 | msn.comSee More Headlines OPRX Stock Analysis - Frequently Asked Questions How have OPRX shares performed this year? OptimizeRx's stock was trading at $4.86 at the beginning of the year. Since then, OPRX stock has increased by 14.1% and is now trading at $5.5450. View the best growth stocks for 2025 here. How were OptimizeRx's earnings last quarter? OptimizeRx Co. (NASDAQ:OPRX) announced its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.16. The business had revenue of $19.69 million for the quarter, compared to analysts' expectations of $18.66 million. OptimizeRx had a negative net margin of 27.41% and a negative trailing twelve-month return on equity of 4.92%. Who are OptimizeRx's major shareholders? OptimizeRx's top institutional shareholders include Whetstone Capital Advisors LLC (7.33%), Royce & Associates LP (5.81%), Blair William & Co. IL (3.26%) and Kennedy Capital Management LLC (3.22%). Insiders that own company stock include William J Febbo, James Paul Lang, Marion Odence-Ford, Stephen L Silvestro, Edward Stelmakh and Ellen O'connor Vos. View institutional ownership trends. How do I buy shares of OptimizeRx? Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of OptimizeRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that OptimizeRx investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC). Company Calendar Last Earnings5/14/2024Today2/24/2025Next Earnings (Estimated)4/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry Business services, not elsewhere classified Sub-IndustryBusiness Services Current SymbolNASDAQ:OPRX CUSIPN/A CIK1448431 Webwww.optimizerx.com Phone(248) 651-6568Fax248-453-5529Employees100Year FoundedN/APrice Target and Rating Average Stock Price Target$9.06 High Stock Price Target$16.00 Low Stock Price Target$5.00 Potential Upside/Downside+63.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,570,000.00 Net Margins-27.41% Pretax Margin-37.84% Return on Equity-4.92% Return on Assets-3.41% Debt Debt-to-Equity Ratio0.29 Current Ratio3.23 Quick Ratio3.23 Sales & Book Value Annual Sales$71.52 million Price / Sales1.43 Cash FlowN/A Price / Cash FlowN/A Book Value$6.97 per share Price / Book0.80Miscellaneous Outstanding Shares18,420,000Free Float17,297,000Market Cap$102.14 million OptionableOptionable Beta1.38 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:OPRX) was last updated on 2/24/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?A new Chinese AI software called "DeepSeek" is sending shockwaves through the market. It's advanced enough ...Behind the Markets | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredWhy 2026 will be a disaster for many AmericansWall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | SponsoredPresident Trump Boosts Your 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptimizeRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.